Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29789038 | 1.00 | CHEK1 (0.69) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL31365268 | 0.96 | CHEK1 (0.65) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL11547694 | 0.91 | CHEK1 (0.84) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL14199812 | 0.90 | CHEK1 (0.84) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL20055376 | 0.86 | CHEK1 (0.55) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL68830 | 0.84 | CHEK1 (0.56) | CHEK1L3MBTL1TTRCA12CA2 | |
| SCHEMBL10626360 | 0.84 | CHEK1 (0.79) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL68584 | 0.83 | CHEK1 (0.59) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL1152020 | 0.82 | CHEK1 (1.00) | CHEK1KMT2AL3MBTL1MEN1TTR | |
| SCHEMBL16769638 | 0.82 | CHEK1 (0.51) | CHEK1KMT2AL3MBTL1MEN1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255235-A1 | METAL ORGANIC STRUCTURE, GAS-STORING AGENT COMPRISING SAME, AND GAS STORAGE METHOD USING SAME | 学校法人立教学院 | 2022-12-08 | — | — | WO | disclosed |
| US-20220023829-A1 | AMORPHOUS METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARING THE SAME | ABSORPTION SOLUTIONS LLC | 2022-01-27 | — | — | US | disclosed |
| WO-2020117833-A2 | AMORPHOUS METAL ORGANIC FRAMEWORKS AND METHODS OF PREPARING THE SAME | FRAMERGY INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3514159-A1 | ALUMINIUM METAL ORGANIC FRAMEWORK MATERIAL | The Texas A&M University System (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3143033-B1 | CHROMIUM METAL ORGANIC FRAMEWORKS AND SYNTHESIS OF METAL ORGANIC FRAMEWORKS | TEXAS A & M UNIV SYS (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9951095-B2 | Chromium metal organic frameworks and synthesis of metal organic frameworks | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHEK1 1792/4885KMT2A 3803/4885L3MBTL1 2200/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHEK1 1792/4885KMT2A 3803/4885L3MBTL1 2200/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHEK1 1792/4885KMT2A 3803/4885L3MBTL1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.